BDSI BioDelivery Sciences International Inc.

2.85
+0.00  (0%)
Previous Close 2.85
Open 2.85
Price To book 6.06
Market Cap 158106520
Shares 55,475,972
Volume 395,888
Short Ratio 3.77
Av. Daily Volume 504,714

SEC filingsSee all SEC filings

  1. 8-K - Current report 171134762
  2. 8-K - Current report 171127980
  3. 8-K - Current report 171081644
  4. CT ORDER - Confidential treatment order 171068210
  5. 8-K/A [Amend] - Current report 171066832

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. BDSI settles patent litigation with generic giant Teva
  2. BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
  3. ETFs with exposure to BioDelivery Sciences International, Inc. : October 9, 2017
  4. BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
  5. ETFs with exposure to BioDelivery Sciences International, Inc. : September 28, 2017
  6. BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
  7. BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
  8. BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment
  9. BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
  10. Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman
  11. BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
  12. BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  13. BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman
  14. BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017
  15. Edited Transcript of BDSI earnings conference call or presentation 9-Aug-17 8:30pm GMT
  16. Today's Research Reports on Stocks to Watch: Portola Pharmaceuticals and BioDelivery Sciences International
  17. BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
  18. BioDelivery reports 2Q loss
  19. BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 171134762
  2. 8-K - Current report 171127980
  3. 8-K - Current report 171081644
  4. CT ORDER - Confidential treatment order 171068210
  5. 8-K/A [Amend] - Current report 171066832
  6. 8-K - Current report 171058615
  7. 8-K - Current report 171019756
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018770
  9. 8-K - Current report 17997126
  10. 8-K - Current report 17969694